

Efficacy of intra-articular injection for end stage hip osteoarthritis: can pain and disability be relieved?

Submission date	Recruitment status	<input type="checkbox"/> Prospectively registered
08/07/2005	No longer recruiting	<input type="checkbox"/> Protocol
Registration date	Overall study status	<input type="checkbox"/> Statistical analysis plan
10/02/2006	Completed	<input checked="" type="checkbox"/> Results
Last Edited	Condition category	<input type="checkbox"/> Individual participant data
01/10/2013	Musculoskeletal Diseases	

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Fraser Birrell

Contact details

Institute of Cellular Medicine
Musculoskeletal Research Group
4th Floor Catherine Cookson Building
The Medical School
Framlington Place
Newcastle University
Newcastle
United Kingdom
NE2 4HH
+44 (0)191 222 5548
fraser.birrell@ncl.ac.uk

Additional identifiers

Protocol serial number

NT/41/04/JC

Study information

Scientific Title

Study objectives

Intra-articular injection of either steroids or Hyaluronic Acid (HA) are now being recommended for patients with knee OsteoArthritis (OA), but there is a lack of studies in hip OA to demonstrate its safety and efficacy. Due to lack of adequate guidance, the lack of response in early research may reflect poor accuracy of injection, rather than lack of benefit.

This study, using an injection technique proven to be accurate, will aim to demonstrate the duration of objective improvement in pain, disability (function and patients global health assessment) and objective mobility in patients with end stage hip osteoarthritis with ultrasound guided hip injection compared to standard care.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethical approval was initially obtained [2002] from the Northumberland Ethics committee with revisions to the protocol being approved in Aug 2005, reference number: NLREC 54/2002. Subsequently, approval was also obtained from Newcastle/North Tyneside Committee in Aug 2005, reference number: NNT SSA 05/Q0905/155.

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Hip osteoarthritis

Interventions

The study is a prospective, randomised, blind, controlled (three arm) trial, with a further randomised standard care arm. The four groups are:

1. Standard care (no injection)
2. Standard care and injection of 3 ml normal saline
3. Standard care and injection of 3 ml steroid (depomedrone 120 mg)
4. Standard care and injection of 3 ml durolane (injection will be performed under local anaesthetic with ultrasound guidance)

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

1. Depomedrone
2. Durolane

Primary outcome(s)

1. Visual Analogue Scale (VAS) for global pain
2. Pain and function scales of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
3. Numact (objective activity monitor)

Key secondary outcome(s)

1. Euroqol EQ-5D
2. Outcome Measures in Rheumatoid Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI)

Completion date

01/05/2007

Eligibility

Key inclusion criteria

1. Age >/=50 years
2. Primary hip osteoarthritis
3. Listed for Total Hip Replacement (THR)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Secondary hip OA
2. Collapse of femoral head on anteroposterior pelvic radiograph
3. Listed for bilateral THR
4. Co-morbid conditions resulting in gross lower limb asymmetry (e.g. stroke, amputees, severe leg shortening)
5. Inability to communicate in verbal or written English

Date of first enrolment

01/08/2005

Date of final enrolment

01/05/2007

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Institute of Cellular Medicine

Newcastle

United Kingdom

NE2 4HH

Sponsor information

Organisation

Northumbria Healthcare NHS Trust (UK)

ROR

<https://ror.org/01gfeyd95>

Funder(s)

Funder type

Government

Funder Name

Northumbria Healthcare NHS Trust

Funder Name

NT/41/04/JC - an 'own account' trial, funded via the NHS R&D Support Funding stream

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/01/2011		Yes	No